September 2024 — Monthly Briefing¶

1. What was read¶

745 research articles from 33 of the 33 journals on the roster.

A further 176 records (19% of the 921 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.

General	Cancer	Immune	Bioinfo	Sysbio
427	134	84	254	22

Volume swing against the median month: cancer -28%

Check the source before reading anything into this. Two benign causes account for most of these. bioinfo every January carries the Nucleic Acids Research database issue and runs high. And several journals simply deposit nothing in some months: across the 44 months read, 4 of 33 journals are absent from at least one, worst being Nat Mach Intell (20 months missing, 81 papers in total) and Bioinformatics (4 months missing, 2,905 papers in total). Every journal on the roster contributed this month. Queried directly, PubMed returns zero for those journal-months too — the holes are in the source, reproduced exactly by re-running the harvest. So a swing here is not evidence that a field went quiet, and is not usually evidence that the pipeline broke either.

Largest contributors: Nature 106, Nucleic Acids Res 98, JAMA 90, Science 79, Bioinformatics 66, Cell 41.

2. Net change on the thread curve¶

Thread	This month	Cumulative	Status
`agentic-ai`	—	+4 / −0	too-early
`cell-therapy`	+7	+128 / −39	forming
`ctdna-mrd`	+4 / −2	+44 / −22	forming
`foundation-models`	+2 / −1	+60 / −42	splitting
`immunotherapy-resistance`	+4 / −5	+141 / −59	forming
`interception`	+2 / −1	+75 / −16	forming
`method-credibility`	−6	+6 / −267	crisis
`neoantigen-vaccines`	+2	+53 / −23	forming
`neuro-immune-microbiome-axis`	+3	+100 / −13	forming
`next-gen-checkpoints`	+1	+47 / −30	splitting
`single-cell-3d-genome`	+4	+44 / −15	forming
`suppressive-population-inversion`	−2	+33 / −45	contested

Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.

3. The evidence that moved it¶

A clinical-AI null with the detail to be acted on. 38965432 (Nat Med) builds a dataset of 2,400 real patient cases from MIMIC across four common abdominal pathologies, and a framework that makes a model work the way a clinician does — gather the information, order the tests, reach a diagnosis inside a workflow — rather than answer exam questions. State-of-the-art large language models diagnose significantly worse than physicians across all four pathologies, follow neither diagnostic nor treatment guidelines, and cannot interpret laboratory results. They also fail to follow instructions and are sensitive to both the quantity and the order of the information they are given, which is why the authors say they cannot simply be dropped into existing workflows. The paper's own conclusion is that these models are "not ready for autonomous clinical decision-making". This is a refutation on foundation-models of a kind the thread rarely gets: not a benchmark score but a named failure on each of the things a deployment would need.

Corrected 2026-08-27

The claim and this paragraph both carried a date argument — that the clinical-AI counterweight this corpus had placed in mid-2025 was in the flagship venue in September 2024. threads.yml already supersedes it: Nature Medicine states clinical-AI limitations in titles in 2023-10 and again in 2023-12. The right fix is not a new date but no date. The finding above needs none to carry it, and the stance is unchanged.

4. Refutations¶

(a) Landing on a tracked thread¶

The month's one thread-level refutation is the clinical decision-making paper described in section 3, filed on foundation-models and left there rather than repeated here. Nothing else lands. September 2024 is the quietest month in the 2024 half of the corpus for thread-relevant refutations, and since 2024 was read thread-first rather than exhaustively, that should be read as a limit on the reading rather than a fact about the month.

(b) Method credibility¶

39322959 (Genome Biol): a realistic benchmark for differential-abundance testing and confounder adjustment in human microbiome studies — the direct methodological successor to May's Nature Medicine confounders paper, four months later, and evidence that the objection was taken up rather than absorbed.

39227979: a multiple-imputation procedure outperforms complete-case and single imputation in differential expression. The default handling of missing data in the standard pipeline is wrong.

39152037 (Genome Res) proposes the smallest change to standard sequence alignment that would let a search sum the probabilities of alternative alignments instead of scoring one: it makes chance similarity easier to judge, finds distant relationships that single-alignment scoring misses, and costs almost nothing in run time. A single-author methods paper, carried here as a note rather than as a ledger entry.

Corrected 2026-08-27

This entry read: "Simple-beats-complex again, and this is the third instance in 2024 alone — January's linear brain dynamics, March's convolutions, September's alignment probabilities. A genre this corpus first recorded as a 2026 phenomenon is running at roughly one paper a quarter in 2024." The word "simple" in a title was matched to a motif the corpus likes. The paper examines no published tool and reports no adverse finding, so it is not an audit and its stance is now neutral. The chain it anchored has also lost its January link: the linear-brain-dynamics paper was removed from foundation-models on the same grounds, that a shared slogan is not a shared result. Counting a genre by matching adjectives across titles produced a trend out of three unrelated papers.

5. Open items¶

Nothing carried forward.

6. Meetings¶

No abstract book published this month. The abstract layer runs 2023-02 to 2026-08 and is seasonal by nature — meetings are annual, so most months are empty here and that is the expected shape, not a gap in the harvest.

7. Regulatory¶

Event	Count
trial-first-posted	388 (of which 345 genuinely oncology)
ema-authorisation	14
fda-approval	7

7 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:

2024-09-12 — FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
2024-09-17 — FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
2024-09-17 — FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
2024-09-19 — FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
2024-09-20 — FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
2024-09-25 — FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
2024-09-27 — FDA approves selpercatinib for medullary thyroid cancer with a RET mutation

5 EMA oncology authorisations:

2024-09-19 — Tuznue
2024-09-19 — Loqtorzi
2024-09-19 — Vyloy
2024-09-19 — Axitinib Accord
2024-09-19 — Ituxredi

8. Trade press¶

57 on-topic of 318 items across 3 feeds (n-stat 304, n-aacr-blog 10, n-acir 4). Headlines are selected by subject keyword, not recency — most of what these feeds carry is health policy and industry finance the corpus does not read.

2024-09-30 — Cancer Screening for All: A Revolutionary Approach to Accessible, Best-in-Class, Multi-Cancer Early Detection — n-aacr-blog
2024-09-30 — STAT+: Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb — n-stat
2024-09-27 — Editors’ Picks, September 2024: Reducing Pancreatic Cancer Risk, Immunotherapy for Dogs, and More — n-aacr-blog
2024-09-27 — STAT+: Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD — n-stat
2024-09-27 — STAT+: Why are Genentech cancer researchers worried? — n-stat
2024-09-27 — STAT+: Dispute over Duchenne gene therapy highlights thorny access issues — n-stat
2024-09-27 — Opinion: Sequencing wastewater material may be the key to getting a grip on the H5N1 bird flu outbreak — n-stat
2024-09-26 — Pancreatic Cancer: The Search for an Achilles Heel — n-aacr-blog
2024-09-26 — STAT+: FDA approves schizophrenia drug that could alter how disorder is treated — n-stat
2024-09-26 — Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug — n-stat
2024-09-26 — STAT+: Gene therapy for sickle cell disease remains a tough business model — and may never work — n-stat
2024-09-25 — Can MRIs ensure prostate cancer screening does more good than harm? — n-stat
… and 45 more on-topic items.